InflaRx’s (IFRX) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX) in a report published on Monday,Benzinga reports. The brokerage currently has a $8.00 price objective on the stock.

InflaRx Price Performance

Shares of NASDAQ IFRX opened at $1.71 on Monday. The stock has a market capitalization of $100.68 million, a PE ratio of -1.58 and a beta of 1.57. InflaRx has a fifty-two week low of $1.17 and a fifty-two week high of $2.10. The business has a fifty day moving average price of $1.53 and a two-hundred day moving average price of $1.51.

Institutional Trading of InflaRx

A hedge fund recently raised its stake in InflaRx stock. Ikarian Capital LLC lifted its stake in shares of InflaRx (NASDAQ:IFRX) by 2.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 704,987 shares of the company’s stock after buying an additional 16,383 shares during the period. Ikarian Capital LLC owned about 1.20% of InflaRx worth $1,086,000 as of its most recent SEC filing. 42.39% of the stock is currently owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.